SCHEMBL22470118

SCHEMBL22470118

CC(C)(C)OC(=O)N1CCC1C(=O)NC1(c2ccc(F)c(OC(F)(F)F)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.42
ALDH1A1 P00352 1/20 0.41
PDE2A O00408 5/20 0.40
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NPC1 O15118 2/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP30 Q70CQ3 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
RET P07949 1/20 0.35
APP P05067 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29358321 1.00 KCNN4 (0.42) KCNN4ALDH1A1PDE2ALMNANPSR1
SCHEMBL29262043 0.87 ALDH1A1 (0.42) KCNN4ALDH1A1PDE2ALMNANPSR1
SCHEMBL22470105 0.87 ALDH1A1 (0.42) KCNN4ALDH1A1PDE2ALMNANPSR1
SCHEMBL22470110 0.83 KCNN4 (0.43) KCNN4ALDH1A1PDE2AUSP30NR1H2
SCHEMBL29356640 0.83 KCNN4 (0.43) KCNN4ALDH1A1PDE2AUSP30NR1H2
SCHEMBL28650895 0.79 APP (0.46) KCNN4ALDH1A1LMNANPSR1NPC1
SCHEMBL28650893 0.79 APP (0.46) KCNN4ALDH1A1LMNANPSR1NPC1
SCHEMBL28664702 0.79 APP (0.46) KCNN4ALDH1A1LMNANPSR1NPC1
SCHEMBL28670102 0.76 KCNN4 (0.37) KCNN4ALDH1A1PDE2ALMNANPSR1
SCHEMBL28670100 0.76 KCNN4 (0.37) KCNN4ALDH1A1PDE2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2026-02-19 US disclosed
US-12391644-B2 Potassium channel inhibitors SANIONA A/S (DK) 2025-08-19 US disclosed
EP-3941903-B1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2025-07-16 EP disclosed
US-20240368077-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2024-11-07 US disclosed
US-12006289-B2 Potassium channel inhibitors SANIONA A/S (DK) 2024-06-11 US disclosed
CN-113631538-B Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2024-05-31 CN disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP disclosed
CN-113631538-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2021-11-09 CN disclosed
WO-2020193419-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391644-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885ALDH1A1 2342/4885PDE2A 999/4885
US-20240368077-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885ALDH1A1 2868/4885PDE2A 730/4885
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885ALDH1A1 2868/4885PDE2A 730/4885
US-12006289-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885ALDH1A1 2342/4885PDE2A 999/4885
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SCN10A, KCNK10, KCNJ2 KCNN4 43/4885ALDH1A1 3723/4885PDE2A 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.